Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Revenue (2016 - 2026)

Ironwood Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $47.7 million for Q4 2025.

  • On a quarterly basis, Revenue fell 47.31% to $47.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $296.2 million, a 15.72% decrease, with the full-year FY2025 number at $296.2 million, down 15.72% from a year prior.
  • Revenue hit $47.7 million in Q4 2025 for Ironwood Pharmaceuticals, down from $122.1 million in the prior quarter.
  • Over the last five years, Revenue for IRWD hit a ceiling of $122.1 million in Q3 2025 and a floor of $41.1 million in Q1 2025.
  • Historically, Revenue has averaged $95.7 million across 5 years, with a median of $100.6 million in 2021.
  • The widest YoY moves for Revenue: up 33.26% in 2025, down 47.31% in 2025.
  • Tracing IRWD's Revenue over 5 years: stood at $117.1 million in 2021, then decreased by 8.48% to $107.2 million in 2022, then rose by 9.66% to $117.6 million in 2023, then fell by 22.98% to $90.5 million in 2024, then tumbled by 47.31% to $47.7 million in 2025.
  • Business Quant data shows Revenue for IRWD at $47.7 million in Q4 2025, $122.1 million in Q3 2025, and $85.2 million in Q2 2025.